OncoResponse is a clinical stage, privately held immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company’s lead candidate, OR2805, has entered clinical studies with a unique and transformative approach to the advancement of cancer therapeutics. OncoResponse is based in Seattle, Washington.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $27M
Founded date: 2016
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 19.05.2023 | Grant | $27M | Takeda Ven... | finsmes.co... |
Mentions in press and media 2
| Date | Title | Description | Source |
| 23.06.2023 | New app rolls through hundreds of local stories for road tri... | There's almost no better education on the state of Texas than driving through it — almost. The only ... | houston.in... |
| 18.05.2023 | OncoResponse Raises $14M; Awarded $13M in Funding | OncoResponse, a Seattle, WA-based clinical-stage biotech company, raised $14M in funding. The round... | finsmes.co... |